[Click eStock] "Cha Vaccine Institute, Another Hidden Champion"

[Asia Economy Reporter Jang Hyowon] On the 27th, KB Securities analyzed Cha Vaccine Research Institute as another hidden champion.

Founded in 2000, Cha Vaccine Research Institute is a specialized company developing next-generation vaccines and immunotherapies using an adjuvant platform. Based on the adjuvant platform technologies ‘L-pampo™’ and ‘Lipo-pam™’, it is developing chronic hepatitis B treatment vaccines, preventive vaccines, and shingles preventive vaccines. An adjuvant is a vaccine additive that can enhance the immunogenicity of vaccine antigens.

Researcher Lim from KB Securities explained, “Cha Vaccine Research Institute’s greatest strength lies in the pipeline scalability from infectious diseases to cancer treatment based on its self-developed adjuvant platform technology,” adding, “Recently, they are developing first-in-class innovative vaccines through L-pampo.”

Researcher Lim said, “The Phase 2b clinical trial of the chronic hepatitis B treatment vaccine (CHI-HBV-002) is progressing smoothly,” and added, “This is a hepatitis B treatment vaccine combining the third-generation recombinant hepatitis B antigen (L-HBsAg) with the ‘L-pampo’ platform.”

He noted, “Meaningful data (such as s-antigen specific immune cell activation and s-antigen reduction) were derived even in the Phase 1/2a trial,” and predicted, “If positive data similar to the Phase 1/2a trial are confirmed in the Phase 2b trial, expectations for future technology export could increase.”

The value of developing the world’s first hepatitis B preventive vaccine (CVI-HBV-002) for non-responders is also highlighted. The third-generation vaccine for non-responders, for whom there is no alternative with existing hepatitis B vaccines, is currently in Phase 1 clinical trials, with interim data expected to be announced early this year.

Additionally, Researcher Lim stated, “In December, the domestic Phase 1 IND for the shingles vaccine candidate ‘CVI-VZV-001’ was approved,” and added, “This candidate is attracting attention as a vaccine that could be developed for shingles prevention (Best in Class) and prevention of postherpetic neuralgia (First in Class).”

This content was produced with the assistance of AI translation services.